1 |
Akintoye, S. O., Lam, T., Shi, S., Brahim, J., Collins, M. T. and Robey, P. G. 2006. Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38, 758-768.
DOI
|
2 |
Aubin, J. E. 2001. Regulation of osteoblast formation and function. Rev. Endocr. Metab. Disord. 2, 81-94.
DOI
|
3 |
Fukumoto, S. 2009. The role of bone in phosphate metabolism. Mol. Cell Endocrinol. 310, 63-70.
DOI
|
4 |
Helms, J. A. and Schneider, R. A. 2003. Cranial skeletal biology. Nature 423, 326-331.
DOI
|
5 |
Hessle, L., Johnson, K. A., Anderson, H. C., Narisawa, S., Sali, A., Goding, J. W., Terkeltaub, R. and Millan, J. L. 2002. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc. Natl. Acad. Sci. USA 99, 9445-9449.
DOI
|
6 |
Hui, M. and Tenenbaum, H. C. 1998. New face of an old enzyme: alkaline phosphatase may contribute to human tissue aging by inducing tissue hardening and calcification. Anat. Rec. 253, 91-94.
DOI
|
7 |
Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, O., Oba, K., Yang, I. M., Miyauchi, A., Econs, M. J., Lavigne, J. and Juppner, H. 2003. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348, 1656-1663.
DOI
|
8 |
Juffroy, O., Noel, D., Delanoye, A., Viltart, O., Wolowczuk, I. and Verwaerde, C. 2009. Subcutaneous graft of D1 mouse mesenchymal stem cells leads to the formation of a bone-like structure. Differentiation 78, 223-231.
DOI
|
9 |
Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H. S., Juppner, H. and Jonsson, K. B. 2004. Transgenic mice expressing fibroblast growth factor 23 under the control of the Alpha1 (I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145, 3087-3094.
DOI
|
10 |
Li, Y., He, X., Olauson, H., Larsson, T. E. and Lindgren, U. 2013. FGF23 affects the lineage fate determination of mesenchymal stem cells. Calcif. Tissue Int. 93, 556-564.
DOI
|
11 |
Murali, S. K., Roschger, P., Zeitz, U., Klaushofer, K., Andrukhova, O. and Erben, R. G. 2016. FGF23 regulates bone mineralization in a 1,25(OH) D and Klotho-Independent manner. J. Bone Miner. Res. 31, 129-142.
DOI
|
12 |
Perwad, F., Zhang, M. Y., Tenenhouse, H. S. and Portale, A. A. 2007. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25- hydroxyvitamin D-1Alpha-hydroxylase expression in vitro. Am. J. Physiol. Renal Physiol. 293, F1577-1583.
DOI
|
13 |
Saji, F., Shigematsu, T., Sakaguchi, T., Ohya, M., Orita, H., Maeda, Y., Ooura, M., Mima, T. and Negi, S. 2010. Fibroblast growth factor 23 production in bone is directly regulated by 1{Alpha},25-dihydroxyvitamin D, but not PTH. Am. J. Physiol. Renal Physiol. 299, F1212-1217.
DOI
|
14 |
Quarles, L. D. 2012. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8, 276-286.
DOI
|
15 |
Quarto, N., Wan, D. C., Kwan, M. D., Panetta, N. J., Li, S. and Longaker, M. T. 2010. Origin matters: differences in embryonic tissue origin and Wnt signaling determine the osteogenic potential and healing capacity of frontal and parietal calvarial bones. J. Bone Miner. Res. 25, 1680-1694.
|
16 |
Razzaque, M. S. and Lanske, B. 2007. The emerging role of the fibroblast growth factor-23-Klotho axis in renal regulation of phosphate homeostasis. J. Endocrinol. 194, 1-10.
DOI
|
17 |
Shalhoub, V., Ward, S. C., Sun, B., Stevens, J., Renshaw, L., Hawkins, N. and Richards, W. G. 2011. Fibroblast growth factor 23 (FGF23) and Alpha-Klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif. Tissue Int. 89, 140-150.
DOI
|
18 |
Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K. and Yamashita, T. 2004. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113, 561-568.
DOI
|
19 |
Sitara, D. 2007. Correlation among hyperphosphatemia, type II sodium phosphate transporter activity, and vitamin D metabolism in Fgf-23 null mice. Ann. N Y Acad. Sci. 1116, 485-493.
DOI
|
20 |
Sitara, D., Kim, S., Razzaque, M. S., Bergwitz, C., Taguchi, T., Schuler, C., Erben, R. G. and Lanske, B. 2008. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 4, e1000154.
DOI
|
21 |
Takei, Y., Minamizaki, T. and Yoshiko, Y. 2015. Functional diversity of fibroblast growth factors in bone formation. Int. J. Endocrinol. 2015, 729352.
|
22 |
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S. and Yamashita, T. 2006. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770-774.
DOI
|
23 |
Wang, H., Yoshiko, Y., Yamamoto, R., Minamizaki, T., Kozai, K., Tanne, K., Aubin, J. E. and Maeda, N. 2008. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J. Bone Miner. Res. 23, 939-948.
DOI
|
24 |
Xiao, L., Esliger, A. and Hurley, M. M. 2013. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J. Bone Miner. Res. 28, 35-45.
DOI
|
25 |
Xiao, L., Naganawa, T., Lorenzo, J., Carpenter, T. O., Coffin, J. D. and Hurley, M. M. 2010. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J. Biol. Chem. 285, 2834-2846.
DOI
|
26 |
Zadik, Y. and Nitzan, D. W. 2012. Tumor induced osteomalacia: a forgotten paraneoplastic syndrome? Oral Oncol. 48, e9-10.
DOI
|